AU2007323925A1 - Method for treating age-related macular degeneration - Google Patents

Method for treating age-related macular degeneration Download PDF

Info

Publication number
AU2007323925A1
AU2007323925A1 AU2007323925A AU2007323925A AU2007323925A1 AU 2007323925 A1 AU2007323925 A1 AU 2007323925A1 AU 2007323925 A AU2007323925 A AU 2007323925A AU 2007323925 A AU2007323925 A AU 2007323925A AU 2007323925 A1 AU2007323925 A1 AU 2007323925A1
Authority
AU
Australia
Prior art keywords
antibody
vegf
antibodies
region
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007323925A
Other languages
English (en)
Inventor
Naveed Shams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2007323925A1 publication Critical patent/AU2007323925A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007323925A 2006-11-10 2007-11-09 Method for treating age-related macular degeneration Abandoned AU2007323925A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86538006P 2006-11-10 2006-11-10
US60/865,380 2006-11-10
PCT/US2007/084320 WO2008063932A2 (en) 2006-11-10 2007-11-09 Method for treating age-related macular degeneration

Publications (1)

Publication Number Publication Date
AU2007323925A1 true AU2007323925A1 (en) 2008-05-29

Family

ID=39323041

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007323925A Abandoned AU2007323925A1 (en) 2006-11-10 2007-11-09 Method for treating age-related macular degeneration

Country Status (6)

Country Link
US (2) US20100111963A1 (enExample)
EP (1) EP2089059A2 (enExample)
JP (1) JP2010509369A (enExample)
AU (1) AU2007323925A1 (enExample)
CA (1) CA2666709A1 (enExample)
WO (1) WO2008063932A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1802334E (pt) * 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
RU2653753C1 (ru) 2008-06-25 2018-05-14 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
KR20180005753A (ko) 2008-06-25 2018-01-16 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
WO2010005527A1 (en) * 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
JP5606438B2 (ja) 2008-07-23 2014-10-15 エフ．ホフマン−ラ ロシュ アーゲー 抗血管新生療法を受容可能な被験体の同定
ES2468827T3 (es) * 2010-01-14 2014-06-17 Sanwa Kagaku Kenkyusho Co., Ltd Producto farmacéutico para prevenir o tratar trastornos acompañados de angiog�nesis ocular y/o permeabilidad vascular ocular elevada
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
KR20140008303A (ko) * 2010-10-27 2014-01-21 노파르티스 아게 안구 혈관 질환의 치료를 위한 투여 요법
KR20180023015A (ko) 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
WO2012105610A1 (ja) * 2011-02-02 2012-08-09 公立大学法人名古屋市立大学 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
US11458199B2 (en) * 2012-08-21 2022-10-04 Opko Pharmaceuticals, Llc Liposome formulations
BR112015003658B1 (pt) * 2012-08-21 2022-09-27 Opko Pharmaceuticals, Llc Formulação oftálmica, uso da dita formulação no tratamento de doença oftálmica do segmento posterior, formulação de lipossomas e suspensão oftálmica lipossomal
JP6470740B2 (ja) * 2013-06-07 2019-02-13 ザ ジョンズ ホプキンス ユニバーシティ 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム
WO2015052104A1 (en) * 2013-10-08 2015-04-16 F. Hoffmann-La Roche Ag Use of n-(4-tert-butylbenzyl)-3-chloro-n-[2-(4-chloro-3-ethyl-phenyl)-ethyl]-2-fluoro- 5-trifluoromethyl-benzamide for the treatment of eye diseases
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
US20180280414A1 (en) * 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
KR101880670B1 (ko) * 2015-11-06 2018-08-16 주식회사 모다이노칩 압력 센서를 구비하는 전자기기
KR20210157427A (ko) 2015-12-03 2021-12-28 리제너론 파마슈티칼스 인코포레이티드 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
EP3515536A1 (en) * 2016-09-19 2019-07-31 Lupin Limited In-line filter for protein/peptide drug administration
KR20200093621A (ko) 2017-11-30 2020-08-05 리제너론 파아마슈티컬스, 인크. 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도
MX2020007948A (es) 2018-02-02 2020-12-10 Univ Kyoto Medicamento para prevenir o tratar una enfermedad oftalmica asociada con neovascularizacion intraocular mejorada y/o permeabilidad vascular intraocular.
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US190317A (en) * 1877-05-01 Improvement in barbers chairs
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
MXPA04007583A (es) * 2002-02-11 2005-04-25 Genentech Inc Variantes de anticuerpo con tasas mas rapidas de asociacion a antigeno.

Also Published As

Publication number Publication date
US20100111963A1 (en) 2010-05-06
WO2008063932A3 (en) 2008-09-04
US20120009185A1 (en) 2012-01-12
WO2008063932A2 (en) 2008-05-29
EP2089059A2 (en) 2009-08-19
JP2010509369A (ja) 2010-03-25
CA2666709A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
AU2005299701B2 (en) Method for treating intraocular neovascular diseases
US20120009185A1 (en) Method for treating age-related macular degeneration
KR102724014B1 (ko) 안 질환의 치료 방법
JP2017536414A (ja) 血管性眼疾患を処置するための方法および製剤
CN104066448A (zh) 眼病的治疗
WO2007011873A2 (en) Method for treating intraocular neovascular diseases
AU2012100335A4 (en) Method for treating intraocular neovascular diseases
AU2011101626A4 (en) Method for treating intraocular neovascular diseases
AU2011101625B4 (en) Method for treating intraocular neovascular diseases
AU2011101622A4 (en) Method for treating intraocular neovascular diseases
AU2011101623A4 (en) Method for treating intraocular neovascular diseases
AU2011101624B4 (en) Method for treating intraocular neovascular diseases
AU2011101627B4 (en) Method for treating intraocular neovascular diseases
HK1102106B (en) Method for treating intraocular neovascular diseases
HK1151222A (en) Method for treating intraocular neovascular diseases
HK1151989A (en) Method for treating intraocular neovascular diseases
HK1151219A (en) Method for treating intraocular neovascular diseases
EA043390B1 (ru) Способы лечения заболеваний глаз антагонистами aplnr и ингибиторами vegf
HK1241908A1 (en) Methods and formulations for treating vascular eye diseases
NZ623275B2 (en) Treatment of ocular disease

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted